Stablepharma, AFT sign vaccine distribution LOI

Stablepharma has signed a letter of intent with AFT Pharmaceuticals to distribute its fridge-free SPVX02 tetanus-diphtheria vaccine in the UK, Canada, Australia and New Zealand, with possible expansion into Singapore and Hong Kong. The move follows positive Phase 1 and stability data and could reduce reliance on cold-chain logistics for vaccine delivery. Why it matters: - Stablepharma is pushing a vaccine designed to work without refrigerated storage or transport. - The proposed deal could expand access to essential vaccines in multiple large markets while easing logistics for health systems and distributors. - The agreement adds momentum to fridge-free pharmaceuticals, which Stablepharma says could improve resilience and sustainability in medicine supply chains. What happened: - Stablepharma Limited signed a letter of intent with AFT Pharmaceuticals for proposed distribution of SPVX02, a fridge-free tetanus-diphtheria vaccine candidate. - The planned territories are the UK, Canada, Australia and New Zealand, with an option to extend into Singapore and Hong Kong. - The announcement came June 15, 2026. - The LOI sets up a proposed long-form distribution agreement in which AFT would hold exclusive distribution rights in the agreed territories, subject to final contract terms and customary conditions. The details: - SPVX02 is advancing toward pivotal Phase 2b clinical trials. - Phase 1 data showed SPVX02 was safe and well tolerated. - The same early trial data showed immunogenicity similar to the originator refrigerated vaccine 28 days after a single dose. - Stablepharma said stability testing showed SPVX02 remained stable at 30°C for 24 months. - That stability profile supports a 36-month shelf-life label for storage up to 30°C for clinical study supply. - Stablepharma also said it has demonstrated GMP production at scale. - The company said that step supports the move from clinical development toward commercial supply. - Stablepharma’s StablevaX platform reformulates vaccines into lyophilised, dry formats designed to stay stable at 30°C from manufacture through expiry without changing the API or compromising clinical performance. - The platform is also being used for SPVX07, a hepatitis B candidate. - Stablepharma says removing the need for refrigerated storage and transport allows medicines to move through standard supply chains. Between the lines: - The LOI follows positive clinical and stability data, so the partnership appears to be moving from proof-of-concept toward commercialization. - The exclusive distribution structure suggests AFT is being positioned as a regional commercialization partner while Stablepharma keeps control of development. - The companies’ January 2026 strategic partnership focused on fridge-free sterile injectables for anti-infective and oncology markets valued at more than USD 6 billion. - The deal also fits broader industry efforts to reduce cold-chain dependence, which can lower costs and cut delivery bottlenecks. What’s next: - Stablepharma will continue leading development of SPVX02. - AFT Pharmaceuticals will handle commercial distribution in the agreed territories if the parties complete a final contract. - The companies plan to work together on clinical, regulatory and commercial milestones ahead of launch. - The proposed agreement could be extended into Singapore and Hong Kong if both sides agree. The bottom line: - Stablepharma is taking its first fridge-free Td vaccine closer to market, and AFT is being lined up to help move it across key international markets.